產(chǎn)品中心Cell Resources
聯(lián)系我們CONTACT US
400-999-210024小時(shí)服務(wù)熱線
sales@procell.com.cn銷(xiāo)售郵箱
PC-3 (人前列腺癌細(xì)胞) (STR鑒定正確)
貨號(hào)：CL-0185
規(guī)格：1×10?cells/T25培養(yǎng)瓶
價(jià)格： ￥1600
生長(zhǎng)培養(yǎng)基：Ham's F-12K＋10% FBS＋1% P/S
產(chǎn)品概述
| 名稱(chēng) | PC-3 (人前列腺癌細(xì)胞) (STR鑒定正確) |
| 別稱(chēng) | PC3; PC.3 |
| 種屬 | 人 |
| 生長(zhǎng)特性 | 貼壁細(xì)胞 |
| 細(xì)胞形態(tài) | 上皮細(xì)胞樣 |
| 凍存條件 | 凍存液：55% 基礎(chǔ)培養(yǎng)基+40%FBS+5%DMSO 溫度：液氮 |
| 培養(yǎng)方案A（默認(rèn)） |
生長(zhǎng)培養(yǎng)基:
培養(yǎng)條件:
氣相：空氣，95%；CO2，5%, 溫度：37℃
|
| 推薦傳代比例 | 1:3-1:4 |
| 推薦換液頻率 | 2-3次/周 |
| 背景描述 | PC-3細(xì)胞源于一位62歲白人男性Ⅳ級(jí)前列腺腺癌患者的骨頭轉(zhuǎn)移灶；PC-3細(xì)胞的酸性磷酸酶活性和5-α-睪丸激素還原酶活性都低。 |
| 年齡（性別） | 男性；62歲 |
| 組織來(lái)源 | 前列腺；骨腺癌轉(zhuǎn)移灶 |
| 細(xì)胞類(lèi)型 | 腫瘤細(xì)胞 |
| 腫瘤類(lèi)型 | 前列腺癌細(xì)胞 |
| 生物安全等級(jí) | BSL-1 |
| 倍增時(shí)間 | ~25-50 hours |
| 致瘤性 | Yes, in semi-solid medium.Yes, tumors developed within 21 days at 100% frequency (5/5) in nude mice inoculated subcutaneously with 1×10^7 cells. |
| 抗原表達(dá)情況 | HLA A1, A9 |
| 基因表達(dá)情況 | HLA A1, A9 |
| 保藏機(jī)構(gòu) | ATCC; CRL-1435 ATCC; CRL-7934DSMZ; ACC-465 ECACC; 90112714 |
STR鑒定
-
STR位點(diǎn)信息
Amelogenin X CSF1PO 11 D2S1338 18,20 D3S1358 16 D5S818 13 D7S820 8,11 D8S1179 13 D13S317 11 D16S539 11 D18S51 14,15 D19S433 14 D21S11 29,31.2 FGA 24 PentaD 9 PentaE 10,17 TH01 6,7 TPOX 8,9 vWA 17 D6S1043 18 D12S391 21 D2S441 10,11 -
STR鑒定圖
-
參考文獻(xiàn)
-
Retinoblastoma-associated protein is important for TRIM24-mediated activation of the mTOR signaling pathway through DUSP2 action in prostate cancer(2024/03/21)
作者：Da Ren, Wei Li, Ruijiang Zeng
期刊：CELL DEATH AND DIFFERENTIATION
DOI：10.1038/s41418-024-01282-w
影響因子 ：12.400
引用產(chǎn)品：CL-0185
-
Targeted Ultrasound Nanobubbles Therapy for Prostate Cancer via Immuno-Sonodynamic Effect(2024/03/18)
作者：Xin Huang, Yueying Chen, Fanglu Zhong
期刊：International Journal of Nanomedicine
影響因子 ：8.000
引用產(chǎn)品：CL-0185
-
PEG-coated and Gd-loaded fluorescent silica nanoparticles for targeted prostate cancer magnetic resonance imaging and fluorescence imaging(2023/01/02)
作者：Wei Jiang, Huiying Fang, Fengqiu Liu
期刊：International Journal of Nanomedicine
影響因子 ：8.000
引用產(chǎn)品：CL-0185
-
Diterpenoid honatisine overcomes temozolomide resistance in glioblastoma by inducing mitonuclear protein imbalance through disruption of TFAM-mediated mtDNA transcription(2023/12/29)
作者：Zongyang Li, Ke Sai, Guoxu Ma
期刊：PHYTOMEDICINE
DOI：10.1016/j.phymed.2023.155328
影響因子 ：7.900
引用產(chǎn)品：CL-0185
-
ND630 controls ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003(2023/12/04)
作者：Yupeng Wu, Wencai Zheng, Qi Huang
期刊：Journal of Translational Medicine
DOI：10.1186/s12967-023-04760-w
影響因子 ：7.400
引用產(chǎn)品：CL-0185
-
Design, Synthesis, and Biological Evaluation of Proteolysis-Targeting Chimeras as Highly Selective and Efficient Degraders of Extracellular Signal-Regulated Kinase 5(2023/09/26)
作者：Pengming Pan, Tongtong Geng, Zhongtang Li
期刊：JOURNAL OF MEDICINAL CHEMISTRY
DOI：10.1021/acs.jmedchem.3c00864
影響因子 ：7.300
-
Bimetallic Nanoplatform Dedicated to Sonodynamic-Calcium Overload Synergistic Therapy via Self-supplied Hydrogen Peroxide and Relieved Hypoxia(2023/12/12)
作者：Wenqian Xu, Yisheng Zhao, Chao Zhang
期刊：Biomaterials Science
影響因子 ：6.600
引用產(chǎn)品：CL-0185
-
Metabolic characterization of sphere-derived prostate cancer stem cells reveals aberrant urea cycle in stemness maintenance(2024/04/22)
作者：Yuanyuan Luo, Jiachuan Yu, Zhikun Lin
期刊：INTERNATIONAL JOURNAL OF CANCER
影響因子 ：6.400
引用產(chǎn)品：CL-0185
-
Risk subtyping and prognostic assessment of prostate cancer based on consensus genes(2022/03/15)
作者：Jialin Meng, Yu Guan, Bijun Wang
期刊：Communications Biology
DOI：10.1038/s42003-022-03164-8
影響因子 ：5.900
引用產(chǎn)品：CL-0185
-
β-hydroxybutyrate inhibits malignant phenotypes of prostate cancer cells through β-hydroxybutyrylation of indoleacetamide-N-methyltransferase(2024/03/30)
作者：Yifan Zhang, Yunlong Li
期刊：Cancer Cell International
DOI：10.1186/s12935-024-03277-6
影響因子 ：5.800
引用產(chǎn)品：CL-0185
-
AID-induced CXCL12 upregulation enhances castration-resistant prostate cancer cell metastasis by stabilizing β-catenin expression(2023/11/23)
作者：Qi Li, Jinfeng Fan, Zhiyan Zhou
期刊：iScience
DOI：10.1016/j.isci.2023.108523
影響因子 ：5.800
引用產(chǎn)品：CL-0185
-
Identification of pyroptosis-related lncRNA signature and AC005253.1 as a pyroptosis-related oncogene in prostate cancer.(2022/09/29)
作者：JiangFan Yu, Rui Tang, JinYu Li
期刊：Frontiers in Oncology
影響因子 ：5.738
引用產(chǎn)品：CL-0185
-
A Liquid–Liquid Phase Separation-Related Index Associate with Biochemical Recurrence and Tumor Immune Environment of Prostate Cancer Patients(2023/03/14)
作者：Qi You, Jiayin Chen, Xiaohui Wu
期刊：INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
影響因子 ：5.600
-
Ferredoxin 1 is a cuproptosis-key gene responsible for tumor immunity and drug sensitivity: A pan-cancer analysis.(2022/09/21)
作者：Longfei Yang, Yuwei Zhang, Yang Wang
期刊：Frontiers in Pharmacology
影響因子 ：5.600
引用產(chǎn)品：CL-0002 CL-0010 CL-0052 CL-0075 CL-0109 CL-0185 CL-0222 CL-0227 CM-H019 PM150110 PM150210 PM150910
-
LOC100996425 acts as a promoter in prostate cancer by mediating hepatocyte nuclear factor 4A and the AMPK/mTOR pathway(2021/08/19)
作者：Xiuyan Wang, Bin Song, Mingcui Zang
期刊：Journal Of Cellular And Molecular Medicine
影響因子 ：5.300
-
MET inhibition enhances PARP inhibitor efficacy in castration-resistant prostate cancer by suppressing the ATM/ATR and PI3K/AKT pathways(2021/11/10)
作者：Sihai Zhou,?Zhihong Dai,?Liang Wang
期刊：Journal Of Cellular And Molecular Medicine
影響因子 ：5.295
-
PCMT1 regulates the migration, invasion, and apoptosis of prostate cancer through modulating the PI3K/AKT/GSK-3β pathway.(2023/10/27)
作者：Jiacheng Zhong, Chao Yuan, Lin Liu
期刊：Aging-US
影響因子 ：5.200
引用產(chǎn)品：CL-0185
-
Synthesis and preclinical evaluation of a novel probe [18F]AlF-NOTA-IPB-GPC3P for PET imaging of GPC3 positive tumor(2024/04/14)
作者：Chunwei Mo, Penghui Sun, Haoran Liang
期刊：BIOORGANIC CHEMISTRY
DOI：10.1016/j.bioorg.2024.107352
影響因子 ：5.100
引用產(chǎn)品：CL-0185
-
177Lu-Labeled Bivalent Ligands of Prostate-Specific Membrane Antigen for Endoradiotherapy of Prostate Cancer(2023/12/28)
作者：Ruoxue Dai, Zhikai Cai, Rui Hu
期刊：MOLECULAR PHARMACEUTICS
DOI：10.1021/acs.molpharmaceut.3c00987
影響因子 ：4.900
引用產(chǎn)品：CL-0185
-
Effect of transmembrane protein 100 on prostate cancer progression by regulating SCNN1D through the FAK/PI3K/AKT pathway(2022/11/11)
作者：Zehua Ye, Yuqi Xia, Lei Li
期刊：Translational Oncology
DOI：10.1016/j.tranon.2022.101578
影響因子 ：4.803
引用產(chǎn)品：CL-0185
-
YTHDF2 protein stabilization by the deubiquitinase OTUB1 promotes prostate cancer cell proliferation via PRSS8 mRNA degradation(2024/03/09)
作者：Xuefeng Zhao, Suli Lv, Neng Li
期刊：JOURNAL OF BIOLOGICAL CHEMISTRY
影響因子 ：4.800
引用產(chǎn)品：CL-0185
-
Cuproptosis enhances docetaxel chemosensitivity by inhibiting autophagy via the DLAT/mTOR pathway in prostate cancer(2023/08/16)
作者：Hongzhuang Wen, Changbao Qu, Zhu Wang
期刊：FASEB JOURNAL
影響因子 ：4.800
-
Comprehensiveness cuproptosis related genes study for prognosis and medication sensitiveness across cancers, and validation in prostate cancer(2024/04/26)
作者：Longfei Yang, Yifan Tang, Yuwei Zhang
期刊：Scientific Reports
DOI：10.1038/s41598-024-57303-8
影響因子 ：4.600
引用產(chǎn)品：CL-0185
-
A pan-cancer analysis of DDR1 in prognostic signature and tumor immunity, drug resistance(2023/04/08)
作者：Longfei Yang, Yuwei Zhang, Yifan Tang
期刊：Scientific Reports
DOI：10.1038/s41598-023-27975-9
影響因子 ：4.600
引用產(chǎn)品：CL-0002 CL-0010 CL-0052 CL-0075 CL-0109 CL-0185 CL-0222 CL-0227 CM-H019 PM150110 PM150210 PM150910
-
Epigenetic activation of METTL14 promotes docetaxel resistance in prostate cancer by promoting pri-microRNA-129 maturation(2024/03/28)
作者：Cheng Wu, Chunqing Miao, Songlin Zhou
期刊：ENVIRONMENTAL TOXICOLOGY
影響因子 ：4.500
引用產(chǎn)品：CL-0185
-
A ratiometric near-infrared fluorescence strategy based on spiropyran in situ switching for tracking dynamic changes of live-cell lysosomal pH(2019/03/27)
作者：Jin Li, Xiaokang Li, Jianbo Jia
期刊：Dyes And Pigments
DOI：10.1016/j.dyepig.2019.03.060
影響因子 ：4.500
-
YAP1 inhibits RSL3-induced castration-resistant prostate cancer cell ferroptosis by driving glutamine uptake and metabolism to GSH(2023/09/29)
作者：Xian Fu, Hongshen Wu, Changjiu Li
期刊：MOLECULAR AND CELLULAR BIOCHEMISTRY
DOI：10.1007/s11010-023-04847-4
影響因子 ：4.300
-
Epigenetic-related Gene-based Prognostic Model Construction and Validation in Prostate Adenocarcinoma(2024/05/08)
作者：Youyou Li, Chao Li, Longxiang Wu
期刊：Heliyon
DOI：10.1016/j.heliyon.2024.e30941
影響因子 ：4.000
引用產(chǎn)品：CL-0185
-
Identification of evodiamine as a suppressor of prostate cancer progression by reducing AR transcriptional activity via targeting Src(2021/10/28)
作者：Pei Cheng,?Xiaofan Zhang,?Xiaofu Wang
期刊：Endocrine
DOI：10.1007/s12020-021-02907-7
影響因子 ：3.925
-
Analyzing roles of small nucleolar RNA host gene 25 from clinical, molecular target and tumor formation in prostate cancer(2023/06/10)
作者：Zelin Liu, Shuai Ke, Qinghua Wang
期刊：EXPERIMENTAL CELL RESEARCH
DOI：10.1016/j.yexcr.2023.113686
影響因子 ：3.700
-
A cuproptosis-related LncRNA signature: Integrated analysis associated with biochemical recurrence and immune landscape in prostate cancer(2023/02/24)
作者：Lei Ren, Xu Yang, Weifeng Wang
期刊：Frontiers in Genetics
DOI：10.3389/fgene.2023.1096783
影響因子 ：3.700
-
NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway(2020/3/28)
作者：Shengjun Luo, Lan Shao, Zhixiong Chen
期刊：Experimental Cell Research
DOI：10.1016/j.yexcr.2020.111981
影響因子 ：3.700
引用產(chǎn)品：CL-0185
-
Crafting a Personalized Prognostic Model for Malignant Prostate Cancer Patients Using Risk Gene Signatures Discovered through TCGA-PRAD Mining, Machine Learning, and Single-Cell RNA-Sequencing(2023/06/07)
作者：Feng Lyu, Xianshu Gao, Mingwei Ma
期刊：Diagnostics
DOI：10.3390/diagnostics13121997
影響因子 ：3.600
-
PEI, a new transfection method, augments the inhibitory effect of RBM5 on prostate cancer(2024/02/21)
作者：Xijia Zhou, Yingshu Cao, Ranwei Li
期刊：BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
DOI：10.1016/j.bbrc.2024.149703
影響因子 ：3.100
引用產(chǎn)品：CL-0185
-
Antitumour activity of TH1579, a novel MTH1 inhibitor, against castration?resistant prostate cancer(2020/11/19)
作者：Mingqiu Hu, Jing Ning, Likai Mao
期刊：Oncology Letters
影響因子 ：2.900
引用產(chǎn)品：CL-0185
-
Silencing of lncRNA MALAT1 inhibits cell cycle progression via androgen receptor signaling in prostate cancer cells(2019/1/7)
作者：Xiaofan Dai, Lingyun Liu, Zuowen Liang
期刊：Pathology Research And Practice
影響因子 ：2.800
-
IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer(2023/08/07)
作者：Yifan Zhang, Yuanpeng Liao, Mayao Luo
期刊：PROSTATE
影響因子 ：2.800
-
GPX2 predicts recurrence-free survival and triggers the Wnt/β-catenin/EMT pathway in prostate cancer(2022/10/25)
作者：Ming Yang, Xudong Zhu, Yang Shen
期刊：PeerJ
影響因子 ：2.700
-
Exploring the role of differentially expressed metabolic genes and their mechanisms in bone metastatic prostate cancer(2023/04/12)
作者：Qingfu Zhang, Peng Zhang, Zhongting Zhao
期刊：PeerJ
影響因子 ：2.700
-
TRPM2-L Participates in the Interleukin-6 Pathway to Enhance Tumor Growth in Prostate Cancer by Hypoxia-Inducible Factor-1α(2023/11/10)
作者：Kai Cheng, Qingmei Jia, Christopher Batbatan
期刊：JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
影響因子 ：2.300
引用產(chǎn)品：CL-0185
-
Inhibitory function of CDK12i combined with WEE1i on castration-resistant prostate cancer cells in?vitro and in?vivo(2023/08/08)
作者：Zheng Qin, Dongze Liu, Yueyao Zhang
期刊：Oncologie
DOI：10.1515/oncologie-2023-0233
影響因子 ：0.900
FAQs
Q：{{item.question}}
A：
產(chǎn)品資料
識(shí)別碼示意圖
娜胡文君.png "邱國(guó)娜/胡文君")
.png "梅文強(qiáng)")
